Blood Proteins Or Globulins, E.g., Proteoglycans, Platelet Factor 4, Thyroglobulin, Thyroxine, Etc. Patents (Class 530/380)
  • Patent number: 10723761
    Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 28, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 10378004
    Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: August 13, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 10202417
    Abstract: The present invention relates to a method for the purification of Vitamin K dependent proteins with high yield and high purity, particularly enriched in active protein, on anion exchange resin materials, to Vitamin K dependent proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 12, 2019
    Assignees: Baxalta Incorporated, Bazalta GmbH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler, Dominik Mittergradnegger
  • Patent number: 9802178
    Abstract: A carrier for blood component adsorption includes a water-insoluble carrier composed of a fiber or particle, the water-insoluble carrier having a surface to which a functional group(s) is/are introduced, the functional group(s) containing an acidic functional group selected from the group consisting of the sulfate group, sulfite group and sulfonate group; and containing an amino group; the fiber having a fiber diameter of, or the particle having a particle diameter of, 0.5 to 20 ?m.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: October 31, 2017
    Assignee: Toray Industries, Inc.
    Inventors: Naotoshi Tomita, Yoshiyuki Ueno, Kazuhiro Tanahashi
  • Patent number: 9796770
    Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: October 24, 2017
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Roni Mintz, Oleg Belyaev, Israel Nur, Liliana Bar, Roberto Meidler
  • Patent number: 9309318
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 12, 2016
    Assignee: Amgen, Inc.
    Inventors: Marc A. Gavin, Ai Ching Lim
  • Patent number: 9193795
    Abstract: Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: November 24, 2015
    Assignee: PROTEONOVA, INC.
    Inventor: Richard B. Williams
  • Patent number: 9175058
    Abstract: The present invention provides methods of treating multiple sclerosis, type 1 diabetes mellitus and other autoimmune diseases by administering a soluble immune response suppressor (SIRS) peptide or a variant thereof to an individual having such disease. The SIRS peptide or variant reduces the severity of or frequency of relapse of multiple sclerosis and reduces the inflammation associated with multiple sclerosis and other autoimmune diseases.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: November 3, 2015
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Staley A. Brod
  • Patent number: 9150903
    Abstract: Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to ?2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the patient. Also provided are methods for the identification of compounds or molecules that increase plasmin activity, comprising determining whether the compound or molecule binds to a binding site on ?2-antiplasmin which increases the conversion of ?2-antiplasmin from an inhibitor to a plasmin substrate, wherein the compound or molecule is not an antibody, thereby identifying a compound or molecule which increases plasmin activity. Further provided are pharmaceutical compositions and methods of use thereof for the treatment of myocardial infarction, thrombosis, ischemic stroke, and pulmonary embolism.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: October 6, 2015
    Assignee: TRANSLATIONAL SCIENCES INC.
    Inventor: Guy L. Reed
  • Patent number: 9061108
    Abstract: An object is to provide a material capable of removing A? from a body fluid efficiently and use of the material, which are developed for the purpose of establishing a therapeutic or preventive method for Alzheimer's disease. Provided is an amyloid ? protein remover, containing a carrier made of any one material selected from the group consisting of cellulose, silica, polyvinyl alcohol, and activated carbon, wherein the carrier does not have an alkyl chain on the surface thereof or has an alkyl chain having 1 to 18 carbon atoms on the surface thereof.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: June 23, 2015
    Assignees: FUJITA HEALTH UNIVERSITY, KANEKA CORPORATION
    Inventors: Nobuya Kitaguchi, Kazunori Kawaguchi
  • Patent number: 9028801
    Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 12, 2015
    Assignees: Electrophoretics Limited, Medical Research Council, University College London
    Inventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
  • Patent number: 9006387
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: April 14, 2015
    Assignee: AbbVie Inc.
    Inventors: Rolf Wagner, John K. Pratt, Dachun Liu, Michael D. Tufano, David A. DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi, Yi Gao, Allan C. Krueger
  • Publication number: 20150094268
    Abstract: The present invention provides a prophylactic or therapeutic agent for a hepatic disease, containing AIM or a partial peptide thereof, or a nucleic acid containing a base sequence encoding the same, a method of screening for a prophylactic or therapeutic agent for a hepatic disease, comprising using an0 animal obtained by loading a non-human mammal deficient in AIM expression with a high fat diet and the like.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 2, 2015
    Inventor: Toru Miyazaki
  • Publication number: 20150079658
    Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: J Milton HARRIS, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas, Anna Mero
  • Publication number: 20150065689
    Abstract: Single step method of enriching highly sialylated variant/s of a protein by use of a strong ion exchange chromatography support and a pH gradient in absence of any salt gradient.
    Type: Application
    Filed: April 8, 2013
    Publication date: March 5, 2015
    Applicant: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Ashish K Patra, Venkata Ramireddy Yeturu, Jaby Jacob
  • Patent number: 8962813
    Abstract: A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth factor (PDGF), Epidermal growth factor (EGF), transforming growth factor alfa (TGF-?), Transforming growth factor beta (TGF-?), insulin like growth factor (IGF-I) and Fibroblast growth factor (FGF) from sources, such as blood, containing the factor for supporting wound healing, wherein the manufacturing process comprises purification steps which are performed in the presence of antithrombin III (AT-III).
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: February 24, 2015
    Assignee: Octapharma AG
    Inventors: Andrea Neisser-Svae, Stefan Winge, Anna Mjärdestam
  • Publication number: 20150045538
    Abstract: The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.
    Type: Application
    Filed: August 19, 2014
    Publication date: February 12, 2015
    Inventors: Shawn F. Bairstow, Jennifer Hutsell, Sindhu Ramachandran
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Publication number: 20150031621
    Abstract: A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 29, 2015
    Inventors: Hubert Brandstaetter, Petra Schulz, Juergen Roemisch
  • Patent number: 8940504
    Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 27, 2015
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Thomas Dock Steenstrup, Peder Lisby Norby
  • Patent number: 8933201
    Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 13, 2015
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
  • Patent number: 8932829
    Abstract: Disclosed are pharmaceutical and synergistic compositions comprising human recombinant alpha-fetoprotein expressed in eucaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: January 13, 2015
    Inventors: Elena Dudich, Lydia Semenkova, Igor Dudich, Eduard Tatulov
  • Publication number: 20150011460
    Abstract: An alpha1-proteinase inhibitor delays the onset or progression of pulmonary exacerbations. In addition, methods delay the onset or diminish the progression of pulmonary exacerbations by the administration of inhaled alpha1-proteinase inhibitor.
    Type: Application
    Filed: November 22, 2012
    Publication date: January 8, 2015
    Inventors: Mark Forshag, Royce Waltrip, Les Garlinghouse, William Barnett
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Publication number: 20140371160
    Abstract: A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t1/2) and the area under blood drug concentration vs. time curve (AUC) are remarkably increased by adding an N-glycosylation site in animal cells through amino acid mutation between 1st and 25th positions of the N-terminus of alpha-1 antitrypsin. Therefore, the alpha-1 antitrypsin variant can be useful in preventing or treating alpha-1 antitrypsin deficiency.
    Type: Application
    Filed: August 13, 2012
    Publication date: December 18, 2014
    Applicant: ALTEOGEN, INC
    Inventors: Soon Jae Park, Hye-Shin Chung, Sang Mee Lee, Ji-Sun Kim
  • Publication number: 20140343253
    Abstract: There is a recognized need for novel, more simplified, approaches to isolation of plasma from whole blood, as well as a need to isolate cell-free plasma fractions containing different plasma proteins. Methods are divulged for use of aqueous phase systems, formed in blood or blood containing solutions via addition of a single polymer at relatively low concentration, to effect isolation (clarification) of plasma proteins from blood cells. Methods are also divulged to replace widely used Cohn-type plasma protein fractionation which is based on sequential addition of up to 40% (v/v) ethanol and other precipitants, with simple sequential addition of a polyacid. The latter results in isolation of plasma protein fractions (i.e. fibrinogen, immunoglobulin, albumin) in sequence similar to that obtained with Cohn Fractionation and therefore may be suitable for use to reduce solvent use and solvent-related process complications in existing plasma protein purification processes.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 20, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: James Van Alstine, Mikael Berg, Johanna Kjorning, JAMIL Shanagar
  • Publication number: 20140315802
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 23, 2014
    Applicant: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20140309166
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Applicant: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Patent number: 8859731
    Abstract: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 14, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mikael Kofod-Hansen, Henning Ralf Stennicke, Soeren Oestergaard, Henrik Oestergaard
  • Publication number: 20140296487
    Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.
    Type: Application
    Filed: November 22, 2013
    Publication date: October 2, 2014
    Applicant: AMBRX, INC.
    Inventors: Joseph SHEFFER, Thea NORMAN, Richard D. DIMARCHI, Anna-Maria A. HAYS PUTNAM, Feng TIAN, Stephanie CHU, Denise KRAWITZ, Ho Sung CHO
  • Patent number: 8846874
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: November 13, 2004
    Date of Patent: September 30, 2014
    Assignee: Hanmi Science Co., Ltd
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 8846869
    Abstract: Provided is a mutant protein capable of binding specifically and quickly to troponin I derived from human myocardium. The mutant protein comprises a first mutant scFv antibody fragment 51 a second mutant scFv antibody fragment 52 and a linker 53. The first mutant scFv antibody fragment 51 comprises a first light chain variable region 51L consisting of an amino acid sequence represented by SEQ ID NO: 76 and a first heavy chain variable region 51H consisting of an amino acid sequence represented by SEQ ID NO: 77. Similarly, the second mutant scFv antibody fragment 52 comprises amino acid sequences of SEQ ID NO: 78 and SEQ ID NO: 79. The linker 53 is provided between the C-terminus of the first heavy chain variable region 51H and the C-terminus of the second heavy chain variable region 52H.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: September 30, 2014
    Assignee: Panasonic Corporation
    Inventor: Takashi Endoh
  • Publication number: 20140275484
    Abstract: The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicants: Baxter Healthcare SA, Baxter International Inc.
    Inventors: Ruth Madlener, Wolfgang Teschner, Hans-Peter Schwarz, Sonja Svatos, Azra Pljevljakovic, Lena Nitsch
  • Patent number: 8828676
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Patent number: 8828939
    Abstract: The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: September 9, 2014
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Kay Hofmann, Hans-Peter Hauser
  • Publication number: 20140249384
    Abstract: In an embodiment, the invention relates to methods, apparatus, computer programs and computer program products for estimating a dry weight of a dialysis patient comprising the steps of determining a first fluid status of the patient between treatment sessions in a first stage, determining a second fluid status of the patient during treatment sessions in a second stage and estimating the dry weight based on the second fluid status.
    Type: Application
    Filed: September 18, 2012
    Publication date: September 4, 2014
    Inventors: Nathan W. Levin, Fansan Zhu, Peter Kotanko, Peter Wabel, Ciro Tetta
  • Patent number: 8821851
    Abstract: Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of humans in the study of inflammatory responses or as screening tools for discovering or developing new therapeutics or lead candidate compounds for inhibition of an inflammatory response.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: September 2, 2014
    Assignees: The General Hospital Corporation, Institut Pasteur
    Inventors: H. Shaw Warren, Jean-Marc Cavaillon
  • Patent number: 8822656
    Abstract: The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 2, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Shawn F. Bairstow, Richard Johnson, Sindhu Ramachandran, Ruth Madlener, Wolfgang Teschner, Hans-Peter Schwarz
  • Patent number: 8816054
    Abstract: Factor VIII variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 26, 2014
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Valder Arruda, Rodney M. Camire, Nicholas Iacobelli
  • Patent number: 8809501
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 19, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8809510
    Abstract: A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a) providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b) performing a cation exchange chromatography in particular as first chromatographic step; c) performing an anion exchange chromatography; d) performing a hydroxyl apatite chromatography; e) followed by ultra/diafiltration to obtain a complement Factor H concentrate.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: August 19, 2014
    Assignee: Octapharma AG
    Inventors: Hubert Brandstaetter, Petra Schulz, Juergen Roemisch
  • Publication number: 20140221616
    Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.
    Type: Application
    Filed: August 20, 2013
    Publication date: August 7, 2014
    Applicants: Ortho-Clinical Diagnostics, Inc., Janssen Pharmaceutica NV
    Inventors: Matthew Garrett DONAHUE, Yong Gong, Rhys Salter, Eric Hryhorenko, Thomas R. DeCory, Bart Remmerie, Banumathi Sankaran
  • Publication number: 20140223588
    Abstract: The application relates to a polypeptide, the amino acid sequence of which is the sequence of a sub-fragment of the C-terminal thioester-cleaved fragment of human alpha-2-macroglobulin (A2M), wherein the molecular weight of said polypeptide is of 36 to 44 kDa, and wherein the first N-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human A2M, is at a position 1,098 or 1,085 or 1,084 or 1,083, and the last C-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human A2M, is one of the last twenty C-terminal amino acids. This polypeptide is differently abundant depending on the stage of liver fibrosis. The application also relates to means deriving therefrom and to the application thereof, notably in the field of hepatitis.
    Type: Application
    Filed: July 27, 2011
    Publication date: August 7, 2014
    Applicant: BIO-RAD INNOVATIONS
    Inventors: Isabelle Catherine Batxelli, Bénédicte Watelet
  • Publication number: 20140213767
    Abstract: The invention relates to compounds of Formula I, wherein L1, L2, and L3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from paliperidone. The invention also relates to conjugates of a paliperidone hapten and a protein.
    Type: Application
    Filed: August 20, 2013
    Publication date: July 31, 2014
    Applicants: Ortho-Clinical Diagnostics, Inc., Janssen Pharmaceutica NV
    Inventors: Pieter Rik HASPESLAGH, Maarten Vliegen, Eric Hryhorenko, Thomas R. DeCory, Banumathi Sankaran
  • Publication number: 20140213766
    Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from olanzipine. The invention also relates to conjugates of an olanzipine hapten and a protein.
    Type: Application
    Filed: August 20, 2013
    Publication date: July 31, 2014
    Applicants: Ortho-Clinical Diagnostics, Inc., JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Garrett DONAHUE, Yong GONG, Rhys SALTER, Eric HRYHORENKO, Thomas R. DeCORY, Bart REMMERIE, Banumathi SANKARAN
  • Publication number: 20140205588
    Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatalytic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.
    Type: Application
    Filed: August 13, 2012
    Publication date: July 24, 2014
    Applicant: THROMBOGENICS NV
    Inventor: Richard Reinier Zwaal
  • Publication number: 20140206844
    Abstract: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (I?Ip). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components.
    Type: Application
    Filed: January 16, 2014
    Publication date: July 24, 2014
    Applicant: ProThera Biologics
    Inventor: Yow-Pin LIM
  • Patent number: 8779094
    Abstract: The present invention also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension with a concentration of at least 20 mg/ml and a solution viscosity of between 2 and 100 centipoise that is suspendable upon shaking or agitation, wherein upon delivery the one or more sub-micron or micron-sized peptides dissolves and do not form peptide aggregates syringeable through a 21 to 27-gauge needle.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: July 15, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Keith P. Johnston, Maria Andrea Mazuski, Joshua Engstrom, Miguel Angelo Rodrigues
  • Patent number: 8772462
    Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: July 8, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
  • Patent number: RE47972
    Abstract: The invention relates to Inter-alpha inhibitor proteins (I?Ip). The invention further relates to processes for purification of I?Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 5, 2020
    Assignee: ProThera Biologics, Inc.
    Inventors: Yow-Pin Lim, Djuro Josic, Douglas C. Hixson